BPC-157: what the current research shows

What BPC-157 is

BPC-157 is a synthetic pentadecapeptide — fifteen amino acids — corresponding to a partial sequence of body protection compound, a protein identified in human gastric juice. It is not a naturally occurring peptide in its own right; it is a fragment that was synthesised and then studied.

Its most-cited practical property is stability: unlike many peptides, it has been reported to remain intact in human gastric juice for extended periods, which is why so much of the animal literature uses oral administration.

The research landscape

The overwhelming majority of published BPC-157 work is preclinical, and a large proportion of it originates from a small number of research groups, principally in Croatia. That concentration is itself a feature of the evidence base worth knowing about.

Published animal work has examined BPC-157 in models of:

• tendon and ligament injury, including transected Achilles tendon in rats;
• muscle crush and laceration injury;
• gastrointestinal mucosal damage, including NSAID-induced and ethanol-induced lesions;
• inflammatory bowel models;
• bone defect healing;
• various vascular and nerve injury models.

Across these, the reported direction of effect has been broadly consistent — but consistency within a narrow group of laboratories is not the same thing as independent replication, and the field does not yet have much of the latter.

Proposed mechanisms

Several mechanisms have been proposed in the literature. None is settled.

Angiogenic signalling

Upregulation of vascular endothelial growth factor receptor 2 (VEGFR2) has been reported, along with downstream effects on endothelial cell migration and tube formation in vitro.

Nitric oxide pathway interaction

A number of studies report that BPC-157 effects are modulated by NO-synthase inhibitors and donors, suggesting interaction with nitric oxide signalling.

Growth factor and collagen expression

Changes in expression of growth hormone receptor and in collagen organisation have been described in tendon-derived cell work.

Human data

There is very little. As of this update there are no published large-scale, randomised, placebo-controlled human efficacy trials of BPC-157 for any indication. Early-phase work relating to inflammatory bowel disease has been referenced in the literature, but it does not constitute an established human evidence base.

The honest summary is that the animal literature is substantial and the human literature is close to absent. Any statement about what BPC-157 does in people is, at present, an extrapolation rather than a finding.

Regulatory context

This changes, and it is the question researchers most often arrive on this page asking about. The current position, stated factually:

• Not an approved drug. BPC-157 has not been approved by the FDA or by comparable authorities for any indication.
• 503A bulk substances list. In 2023 the FDA placed BPC-157 in Category 2 of its review of bulk drug substances nominated for use in compounding — the category for substances that raise significant safety risks. The practical effect is that it is not available for pharmacy compounding under that pathway.
• Prohibited in sport. The World Anti-Doping Agency has listed BPC-157 as a prohibited substance at all times since January 2022, under the non-approved substances category.
• Sold as a research chemical. Material supplied for laboratory research, including ours, is supplied on that basis only.

We are not going to speculate on where this goes next. If the position changes, this section changes with it, and the date at the top of the page records when.

Limits of this evidence

Four limitations apply to essentially all of the above, and they are worth holding onto:

• Species. Nearly all of it is rodent work. Rodent tissue repair is not human tissue repair.
• Concentration of sources. A narrow set of laboratories produced a large share of the positive findings.
• Publication bias. Negative results in this area are rarely published, so the visible literature is likely skewed.
• Model artificiality. Induced injury in a controlled animal model is a deliberately simplified system.